White Ox,
As per the quote from our Chairman:
"Our market are products with actual clinical claims associated with them that requires regulatory approval.”There’s just one company that has brought a cannabis-based product through clinical trials to gain approval: GW Pharmaceuticals (NASDAQ:GWPH), the Ireland-based company that was acquired earlier this month by Jazz Pharmaceuticals (NASDAQ:JAZZ) in a blockbuster $US7.2 billion ($9.4 billion) deal.
So I believe on commencement of human trials, we are worth more than $100m and success-- well the above says it all.
Plenty of upside here, and someone at pershings thinks so too, as I think since Jan 1st they have bought - net ,over 15m shares.
Interesting times.
Cheers
White Ox, As per the quote from our Chairman:"Our market are...
Add NTI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $92.58M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 86 | 9.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.2¢ | 6584 | 3 |
View Market Depth
| Last trade - 16.12pm 03/05/2024 (20 minute delay) ? |
| NTI (ASX) Chart |
Day chart unavailable